Stamp authority orders Rs 59.5 Cr duty and penalty on 2022 demerger; company to challenge
AARTIPHARM · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 0.5 pts less than Nifty Microcap 250 and 0.3 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Aarti Pharmalabs received an order from the Superintendent of Stamps, Gandhinagar dated August 29, 2026, levying stamp duty of Rs 25 Cr, penalty equal to deficient duty of Rs 25 Cr, and an additional penalty of Rs 9.5 Cr, totalling Rs 59.5 Cr. This relates to the 2022 demerger of Aarti Industries pharma division into Aarti Pharmalabs, approved by NCLT Ahmedabad. The company states it will challenge the order, citing strong factual and legal grounds. Financial impact is quantified at Rs 59.5 Cr pending appeal.
Potential Rs 59.5 Cr financial liability from stamp duty penalty; company plans to appeal, so final impact remains uncertain.